ad image

Vertex Pharmaceuticals

1 / 1
Vertex
Collaboration

Vertex and Obsidian Therapeutics Establish Collaboration to Discover Novel Therapies That Regulate Gene Editing

Vertex

PR-M04-21-024Apr 22, 2021
Vertex
Gene Editing

Vertex Announces New Clinical Data for Investigational Gene-Editing Therapy CTX001™ in Severe Hemoglobinopathies

Vertex

PR-M06-20-NI-017Jun 12, 2020
Vertex
Cell and Gene Therapy

CRISPR Therapeutics and Vertex Announce Positive Safety and Efficacy Data From First Two Patients Treated With Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001® for Severe Hemoglobinopathies

Vertex

PR-M11-19-NI-023Nov 20, 2019
Vertex
Agreement

Vertex Announces New Access Agreement with Scottish Government for ORKAMBI® (lumacaftor/ivacaftor) and SYMKEVI® (tezacaftor/ivacaftor)

Vertex

PR-M09-19-NI-041Sep 16, 2019
Vertex
M&A

Vertex to Acquire Semma Therapeutics With a Goal of Developing Curative Cell-Based Treatments for Type 1 Diabetes

Vertex

PR-M09-19-NI-008Sep 04, 2019
Vertex
Leadership

Vertex Announces Dr. Jeffrey Leiden to Transition to Role of Executive Chairman and Dr. Reshma Kewalramani Appointed as New CEO

Vertex

PR-M07-19-NI-076Jul 29, 2019
Vertex
FDA Approval

FDA Approves ORKAMBI® (lumacaftor/ivacaftor) as First Medicine to Treat the Underlying Cause of Cystic Fibrosis for Children Ages 2-5 Years with Most Common Form of the Disease

Vertex

PR-M08-18-NI-075Aug 20, 2018
BNBuilders
Research

BNBuilders Completes Construction on Vertex Pharmaceuticals Research Center in San Diego

BNBuilders

PR-M06-18-NI-082Jun 26, 2018
1 / 1